Belantamab (Anti-TNFRSF17 / BCMA / CD269)
Belantamab (Anti-TNFRSF17 / BCMA / CD269) (A2328-GRP)
Products
Description
Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2328 |
| Target | CD markers |